ReviewMicrobial cell factories2026
Untapped microbial factories for next-generation therapeutics: Endophytic fungi of medicinal plants.
Review in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unveiling the diversity, bioactive metabolites and therapeutic potential of endophytic fungi of the Apocynaceae family: a comprehensive review.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endophytic fungi residing within medicinal plants represent a rich and sustainable source of bioactive secondary metabolites with diverse pharmacological applications. These symbiotic microorganisms establish mutualistic relationships with their host plants, contributing to enhanced stress tolerance, growth promotion, and defense against pathogens. In recent years, endophytic fungi have gained considerable attention as alternative biofactories for the production of valuable compounds such as alkaloids, terpenoids, phenolics, lignans, and polysaccharides. These metabolites exhibit a wide range of biological activities, including antimicrobial, antiviral, anticancer, antioxidant, anti-inflammatory, and antidiabetic effects. Advances in cultivation strategies, such as OSMAC, co-culture, and epigenetic modification, have significantly improved metabolite yield and diversity. Moreover, the integration of genomics, transcriptomics, and metabolomics has revolutionized the understanding of biosynthetic gene clusters and metabolic pathways, enabling the discovery of novel compounds and optimization of production processes. Despite these advances, challenges such as low yield, silent gene clusters, and difficulties in large-scale production remain significant barriers. Nevertheless, continued progress in multi-omics technologies, synthetic biology, and biotechnological tools holds great promise for unlocking the full potential of endophytic fungi. Herein, endophytic fungi represent a powerful and eco-friendly platform for the development of new therapeutic agents and sustainable pharmaceutical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.